1. No category

CURRICULUM VITAE
THOMAS EDWARD KEANE, M.B.B.Ch., F.R.C.S.I., F.A.C.S.
Office address:
Medical University of SC
Department of Urology
96 Jonathan Lucas Street
CSB644
Charleston, SC 29425
Phone: (843) 792-1666
Fax: (843) 792-8523
Education:
1967-1975
Learning Cert.
Belvedere College, Dublin
1975-1981
M.B. B.Ch., BAO
University College Dublin.
National Univ. of Ireland.
1981-1982
Intern
Medicine/Surgery
Professor: N.O. Higgins
St. Vincent’s Hospital
Elm Park
Dublin 4
1982-1983
Anat. Demonstratorship
Professor N.O. Higgins
University College Dublin
National University of Ireland
1983-1986
Surgical Registrar
Casualty Officer
Senior House Officer
St. Vincent’s Hospital
Elm Park
Dublin 4
1986-1988
Surgical Registrar
GU/General Surgery
Mr. H.B. Devlin
N. Tees General Hospital
Hardwick, Stockton-on-Tees
Cleveland, UK
1988-1993
Urology Resident
Prof. David Paulson
Duke University Med. Center
Durham, NC
Postgraduate Training:
1
T.KEANE REV 05/27/2010
Current Titles and Affiliations:
05/2002 - Present
Professor and Chair
Department of Urology
Medical University of SC
Charleston, South Carolina
Licensures/Boards:
South Carolina
Georgia
issued: 05/02
issued: 10/93
Previous Academic & Professional Appointments:
04/1997 - 04/2002
Vice Chair
Associate Professor
Department of Urology
Emory University
Atlanta, Georgia
04/1997 – 06/1998
Interim Chairman
Department of Urology
Emory University
Atlanta Georgia
04/1993 - 04/2002
Chief of Urology
Grady Memorial Hospital
Atlanta, Georgia
08/1993 - 04/1997
Assistant Professor
Department of Urology
Emory University
Atlanta, Georgia
08/1993 - 04/2002
Dir. of Clinical Research
Department of Urology
Emory University
Atlanta, Georgia
Specialty Boards:
American Board of Urology
February 28, 1995-2015
Previous Administrative Appointments:
Emory University:
1993-2002
1993-1997
1994-1995
2000-2002
Dir. of Clinical Urologic Research, Winship Cancer Center
Cancer Research Review Committee
O.R. Committee
Advisory Committee to CEO of The Emory Clinic
Medical University of South Carolina:
2003
Search Committee for Hollings Cancer Center Chairman
2
T.KEANE REV 05/27/2010
2004
2004-2005
2005
2007
Present
Present
Present
Present
Present
Present
Present
Present
Present
2009
2009
2009
2009
Search Committee for Radiology Dept. Chairman
Search Committee for Radiation Oncology Dept. Chairman
Search Committee for Anesthesia Dept. Chairman
Search Committee for Surgery Dept. Chairman
MUSC Contracts Committee
UMA Board of Directors
GU/Prostate Working Group Committee
Prostate Cancer Program Planning Committee
UMA Nominating Committee
PPG Committee
MUSC Capital Campaign Communications Advisory Panel
MUSC Leadership Evaluation Committee
Hollings Cancer Center Internal Advisory Board
Deans Search Committee
Thesis Defense Committee
Hollings Cancer Center Leadership Council
Conflict of Interest Committee
Committee Memberships:
Renal Committee, Eastern Cooperative Oncology Group, Co-Chairman, Jan. 1998
Southeast Section AUA, Committee on Science and Education, 2005 – 2008
South Carolina Urologic Association, Executive Committee, 2005-2006
AUA/EAU Academic Fellowship Committee, 2003 – 2008
AUA/EAU Academic Fellowship Committee, Chairman 5/2007 – 5/2009
American Board of Urology, 1995 – 2015
Consultantships:
1996 – 1997
1996 – 1998
1998 – 2002
2000 – 2002
2002 – 2005
1998 – 2004
2004 – Present
2007-Present
Pharmacia Upjohn
Miravent
Roberts Pharmaceuticals
Aguron Pharmaceuticals – Biotechnology
Valera Pharmaceuticals
Slainte Pharmaceuticals
Cytogen
Sanofi-Aventis
Editorships & Editorial Boards:
Associate Editor
Co-Editor
Guest Editor
Co-Editor
The 5-Minute Urology Consult, 2nd Edition, 2009
Glenn’s Urologic Surgery, 8th Edition, 2008
Canadian Journal of Urology, Masters in Urology 2007
Glenn’s Urologic Surgery, 7th Edition, 2007
3
T.KEANE REV 05/27/2010
Co-Editor
Consultant Editor
Guest Editor
Guest Editor
Associate Editor
Glenn’s Urologic Surgery, 6th Edition, 2004
Prostate Cancer and Other Prostatic Diseases, 2004
Scientia – Prostate Cancer Update, February 2001
Scientia – Prostate Cancer Update, August 2001
Glenn’s Urologic Surgery, 5th Edition, 1998
Manuscript reviewer:
1998
1999-Present
2000-Present
2000-Present
2000-Present
2000-Present
2004-Present
2004-Present
2004-Present
2005-Present
2005-2008
New York Section of Urology, Valentine Essay Competition.
Urology.
Molecular Urology.
Oncology
Proceedings of the Mayo Clinic.
International Journal of Cancer.
British Journal of Urology
World Journal of Surgery
Journal of Urologic Oncology
Journal of Urology
T. Leon Howard Pyelogram
Honors & awards:
1st Class Honours ENT - 1980
2nd Class Honours Ophthalmology - 1980
Royal Society of Medicine, Nordic Surgical Prize - 1987
Southeastern Section/ AUA, Montague Boyd Prize Winning Assay - 1990, 1991, 1996
Southeastern Section/ AUA, T Leon Howard Pyelogram Conference, 2nd Prize - 1991
Pfizer Scholar in Urology – 1996
Southern Society of Urologic Surgeons, Mims Gage Ochsner Award for Best Scientific
Presentation - 2003
Alpha Omega Alpha - 2005
Society memberships:
1985
1992
1993
1996-Present
1996-Present
1996-Present
Fellow of the Royal College of Surgeons in Ireland
Royal Academy of Medicine in Ireland
Royal Society of Medicine
Irish Society of Gastroenterology
Irish Society of Urology
Society of Basic Urology Research
Atlanta Urology Association
American Urological Association
Southeastern Section, American Urological Association
American College of Surgeons
4
T.KEANE REV 05/27/2010
1996-Present
1996-Present
1996-Present
1998-Present
1998-Present
1999-Present
2002-Present
2008-Present
Society of Surgical Oncology
Dekalb County Medical Society
Fellow, American College of Surgeons.
Southern Society Urologic Surgeons
Society of Urologic Oncology
Society International D’Urologic
South Carolina Urologic Association
Urology Research Society
Organization of National or International Conferences:
1. International Prostate Cancer Symposium, Atlanta, GA, 1996. (Program Chairman)
Presentation: Adjuvant Hormonal therapy for Prostate Cancer
Presentation: Current Research at Emory, Basic and Clinical
2. International Prostate Cancer Symposium, Atlanta, GA, April 18-19, 1997
Presentation: “Clinical Pathways in Prostate Cancer/Radical Perineal
Prostatectomy”
3. International Prostate Cancer Symposium, Atlanta, GA, June 5-6, 1998
Presentation: “Medical Therapy for BPH”
Presentation: “PSA & Screening - A Recent Perspective”
4. International Prostate Cancer Symposium, Atlanta, GA, August 2000. (Program
Chairman)
Presentation: “Current Issues on Prostate Cancer Management”
5. Prostate Cancer Summit, Athens, Greece, June 9-11, 2005. Co-Chairman
Presentation: “Prostate Cancer from 1995- 2005.
6. Bermuda Urologic, Hamilton, Bermuda, July 14-17, 2005. Co-Chairman
Presentation: “Continent Urinary Diversions”
Presentation: “Perineal Prostatectomy”
7. Future Urology International Urology Symposium, Charleston, SC. Sept. 8-10,
2005. (Program Chairman)
8.
9. Prostate Cancer Summit, Amsterdam, Holland, June 29-July 1, 2006. Chairman
10. Bermuda Urologic, Hamilton, Bermuda, August 3 – 6, 2006. Co-Chairman.
11. Future Urology International Urology Symposium, Hamburg, Germany. December
7 – 9, 2006. (Program Chairman)
12. Bermuda Urologic, Hamilton, Bermuda, July 11 – 14, 2007. Co-Chairman.
5
T.KEANE REV 05/27/2010
13. US American – German Exchange on Treatment of Prostate Cancer, Charleston,
SC, December 14 – 15, 2007. Chairman.
14. Bermuda Urologic, Hamilton, Bermuda, July 30 – August 3, 2008. Co-Chairman.
Research Focus:
Translational Research: Utilizing human tumor xenografts to investigate
the efficacy of new therapies as they relate to GU malignancies with
particular reference to cytotoxic agents, sphingolipids and Boron
containing compounds.
Patents Issued:
1. Treatment of Urogenital Cancer with Boron Neutron Capture Therapy. U. S. Serial
No. 08/334.759
2. Sphingolipid Derivatives and Their Use. PCT Application No. US 99/03093
3.
Pending: Sphingolipids
Canadian Patent 2,204,160 Treatment of Urogenital Cancer with Boron Neutron
Capture therapy
Grant Support
Principal Investigator:
1. 1993 Principal Investigator. A Phase 3 Randomized Prospective Trial of
Autolymphocyte Therapy versus Interferon-Alpha in the Treatment of Metastatic
Renal Cell Carcinoma.
2. 1995 Principal Investigator. A Phase 2 Study of Oral Bropirimine in Adult Patients
with BCG Resistant Bladder Carcinoma In Situ or Tolerance to BCG.
3. 1995 Principal Investigator. A Phase 3 Study of Oral Bropirimine versus
Intravesical BCG in Adult Patients with BCG Naive Bladder Carcinoma In Situ.
4. 1995 Principal Investigator. A Phase 3 Study of Suramin in the Treatment of
Advanced Painful Metastatic Prostate Cancer.
5. 1995 Principal Investigator. A Double Blind Randomized, Phase 3, Multicenter
study of Suramin and Hydrocortisone versus Hydrocortisone and Placebo in the
Treatment of Patients with Metastatic, Hormone Refractory Prostate Cancer (Stage
D2).
6. 1996 Principal Investigator: Comparative Study of the Clinical Efficacy of Two
Dosing Regimens of Eulexin.
7. 1996 Principal Investigator: A Randomized, Double Blind, Comparative Trial of
Bicalutamide (Casodex) vs. Placebo in Patients with Early Prostate Cancer.
8. 1996 Principal Investigator: Adults with Extravesical Carcinoma in situ (CIS), BCG
6
T.KEANE REV 05/27/2010
Resistant Bladder CIS, or Bladder CIS and Intolerance to BCG.
9. 1996 Principal Investigator: A Phase III Study of Doxil Cliposomal Doxorubicin in
Patients with Advanced Renal Cell Carcinoma.
10. 1996 Principal Investigator: Boron Neutron Capture Therapy for Prostate Cancer.
Pilot project. Developmental research program in prostate cancer NIH - NCI. R-21
CA69764.
11. 1996 Emory Sphingolipid Initiative. Founding members: D. Liotta, A. Merrill, T.
Keane, K. Balla, F.Hunt. Funded by Georgia Research Alliance. (1997) 1.4 million.
12. 1998 Principal Investigator: A Phase II Study of 9-amino-20S-Camptothecin (9-AC)
in patients with Advanced Renal Cell Carcinoma. Protocol #T96-0110. Approved
by CTPT & NCI.
13. 1998 Principal Investigator: MVAC in Organ Confined Bladder Cancer Based on
P53 Status.
14. 1998 Principal Investigator: Phase II Study of the Matrix Metalloproteinase
Inhibitor AG3340.
15. 1999 Principal Investigator: Extracorporeal Magnetic Innervation (EXMI) for the
Treatment Urinary Incontinence after Radical Prostatectomy.
16. 2002 Principal Investigator: AG 13736 on Angiogenesis and Tumor Growth in Renal
Cell Carcinoma Xenograft. $75,000.
17. 2005 Collaborator: Seed Grant – HLA Class II: Restricted Immune Recognition of
Prostate Cancer. $60,000.
18. 2006 Principal Investigator: GSK: A Randomized, Double-Blind, Placebo-Controlled,
Parallel Group Study of the Efficacy and Safety of Dutasteride 0.5mg Administered
Orally once Daily for Four Years to Reduce the Risk of Biopsy-Detectable Prostate
Cancer. $154,425.
19. 2006 Principal Investigator: MVAC in Organ Confined Bladder Cancer Based on
P53 Status
20. 2006 Principal Investigator: DOD: A Clinical Assessment of Novel Urinary Markers
for Diagnosis and Monitoring of Bladder Cancer Patients. $251,433.80.
21. 2006 Principal Investigator: CDC: Family and Cancer Therapy Selection (FACTS)
Study. $201,756.
22. 2007 Principal Investigator: Abbott: An Open-Label, Phase 2 study to Evaluate the
Efficacy and Tolerability of ABT-869 in subjects with Advanced Renal cell
Carcinoma (RCC) Who have Previously Received Treatment with Sunitinib.
$251,280.
23. 2008 Principal Investigator: AstraZeneca: A Phase III, Randomized, Double-Blind,
Placebo-controlled Study to Assess the Efficacy and Safety of 10mg ZD4054 in
Combination with Docetaxel in Comparison with Docetaxel in Patients with
Metastatic Hormone-resistant Prostate Cancer. $105,186.
24.2009 Principal Investigator: AstraZeneca: A Phase III, Randomized, Double-Blind
Study to Assess the Efficacy and Safety of Once-daily Orally Administered ZD4054
10mg in Non-Metastatic Hormone Resistant Prostate Cancer Patients. $ 105,186.
Co-investigator:
1. 1993 Chemoprevention of Prostate Cancer with Finasteride, (Proscar).
2. 1993 CaP Cure research award: Gene therapy for metastatic prostate cancer.
7
T.KEANE REV 05/27/2010
3. 1995 Developmental Research Program in Prostate Cancer (NIH) Grant#: 523665.
4. 1996 A Clinical Trial of Medical Therapies in Benign Prostatic Hyperplasia. (NIH
BPH Trial) Grant#: 524175.
5. 2000 Naturally Occurring Sphingolipids and Sphingolipid Analogs as Mechanismbase Anti-cancer Agents (NIH). Grant #: 521326. Director of Tissue Culture Core.
4.5 million.
6. 2001 Immune Mediated Clearance of Prostate Tumor Cells. HCC/DOD
N6311601MD10004, $305,154
7. 2002 TRAIL as an Effector Molecule Against Bladder Cancer. DOD
8. 2003 Compliment Inhibitors & Immunotherapy. NIH Grant # R21CA104579
9. 2004 Velcade (bortezomib) for injection therapy for early relapse prostate cancer
10. 2005 A phase Ii study of neo-adjuvant cisplatin, gemcitabine, and bevacizumab,
followed by radical cystectomy for patients with muscle invasive, resectable, nonmetastatic transitional cell carcinoma (TCC) of the bladder
11. 2005 A phase 2 randomized trial for patients with muscle-invading bladder cancer
evaluating transurethral surgery and BID irradiation plus either paclitaxel and
cisplatin or 5-florouracil and cisplatin followed by selective bladder preservation
and gemcitabine/paclitaxel/cisplatin adjuvant chemotherapy
12. 2005 The role of Thromboxane A2 in bladder cancer
13. 2007 A phase I/II trial of a combination of paclitaxel and trastuzumab with daily
irradiation or paclitaxel alone with daily irradiation following transurethral surgery
of non-cystectomy candidates with muscle-invasive bladder cancer.
14. 2007 Recovery of testosterone and PSA after cessation of long term LHRH agonist
therapy for prostate cancer
15. 2008 SCTR: Use of exfoliated cells in urine for detection of cancer and prediction of
treatment susceptibility
16. 2008 CTRF: Vitamin D and Prostate Cancer-effectts of Vitamin D with Prostate
Cancer
17. 2008 Phase III study of docetaxel and atrasentan versus docetaxel and placebo for
patients with advanced hormone refractory prostate cancer
18. 2008 Biobarkers of tumor angiogenesis and response to sunitinib maleate in reanal
cell carcinoma
19. 2008 Phase 3b, randomized, open-label study of bevacizumab (Avastin®)+
Temsirolimus (torisel®) vs. Bevacizumab (Avestin®) + Interferon-alfa (Roferon®) as
first line treatment in subjects with advanced renal cell carcinoma
20. 2008 A phase iii trial of short term androgen deprivation with pelvic lymh node or
prostate bed only radiotherapy (SPORT) in prostate cancer patients with a rising
PSA after radical prostatectomy
21. 2008 Detection of circulating tumor cell in patients with prostate cancer
22. 2008 Aanofi-Aventis: Randomized study of Larotaxel + Cisplatin (LC) Vs.
Gemcitabine + Cisplatin in 1st line treatment of locally advanced/metastiatic
urothelial tract Bladder cancer
23. 2008 A CDC-Funded Research Agenda: Perspectives on Quality of Life following
Prostate Cancer.
24. 2008 Spectrum Pharmaceuticals: A multicenter, randomized, placebo controlled,
double-blind, phase 3 trial of single dose intravesical EOquin® as a surgical
adjuvant instilled in the early postoperative period in patients undergoing
8
T.KEANE REV 05/27/2010
transurethral resection for noninvasive bladder cancer.
9
T.KEANE REV 05/27/2010
Lectureships, Seminar Invitations, Visiting Professorships:
1. Second Uniformed Services Urology Research Group Seminar. “Therapeutic
Options for the Management of Pain in Prostate Carcinoma.” December 11, 1994,
Denver, CO.
2. Seventh Annual Infection Disease Conference for Primary Care Practitioners.
“Urinary Tract Infections in the 90's.” October 19, 1995, Huntsville, AL.
3. Innovations in Diagnosis and Management of Prostate Carcinoma Issues. “Current
Issues in Screening and PSA.” June 6, 1997, Atlanta, GA.
4. Annual Clinical Assembly of Osteopathic Specialists. “Management of Localized
Prostate Cancer.” September 21, 1997, Atlanta, GA.
5. Royal College of Australian Surgeons. “The Perineal or Retropubic Approach to
Prostate Cancer. Which is better?” September 1997, Christchurch, New Zealand.
6. Royal College of Australian Surgeons. “An Update on Urologic Research at Emory
University.” September 1997, Christchurch, New Zealand.
7. Royal College of Australian Surgeons. Visiting Professor - September 1997,
Christchurch, New Zealand.
8. Annual Clinical Assembly of Osteopathic Specialists. “Management of Localized
Prostate Cancer.” September 21, 1997, Atlanta, GA.
9. Essays Judge, New York Section, AUA – 1998.
10. Challenges in Prostate Cancer: An Expert Opinion, National Public Radio: 1998.
11. Trends in Prostate Cancer Management. Urologic Update. Faculty. August 14-15,
1998, Vancouver, Canada.
12. 7th Annual Oncology Update for Primary Care. Alegent Health, Omaha, Nebraska.
Visiting Professor. September 1998.
13. Bristol University Urologic Oncology Workshop. Visiting Professor and Surgeon.
November 8-13, 1998, Bristol, U.K.
14. Wesley Woods Geriatric Update for Primary Care Physicians – Benign Prostatic
Hyperplasia: Medical therapy in the geriatric population, September 16, 1999.
15. XI Congreso Annual de la Asociaciόn de Urologos Espresados Del Centro Medico
“La Raza” Anver “Neoadejuvant and Adjuvant Therapy: Its role in Prostate Cancer.”
“Management and Selection of Patients for Cyst in Bladder Cancer.” “Radical
Perineal Prostatectomy.” Mexico City, Mexico. January 21 and 22, 2000.
16. Matrix Metallic Protease Inhibitors in Prostate Cancer: Miami, Florida, January 27,
2000.
17. Emory Primary Care Update Conference, February 19, 2000:
18. Erectile Dysfunction in the Elderly. Dekalb Medical Center. Medical Grand
Rounds: “Management of Benign Prostatic Diseases.” March 14, 2000.
19. Urology Grand Rounds, Henry Ford Hospital, Detroit, Michigan: “Neoadjuvant and
Adjuvant Hormonal Therapy in Prostate Cancer,” March 15, 2000.
20. Charleston Urologic Society: Management of Superficial Bladder Cancer,
Charleston, S.C. May 9, 2000.
21. Symposium on Management of Prostate Cancer. Program Chairman: Atlanta, GA August 12, 2000.
22. Neoadjuvant and Adjuvant Strategies in Prostate Cancer: Maine Urologic –
Sugarloaf Guest Professor, September 9, 2000.
23. Modern Hormonal Strategies in Prostate Cancer: Beth Israel Hospital, New York 10
T.KEANE REV 05/27/2010
October 12, 2000.
24. New Diagnostic Modalities in Prostate Cancer: Guest speaker, Chattanooga
Urologic Society - November 2, 2000.
25. Guest Professor: New York Resident’s Association – 2000. Advanced Prostate
Cancer: Options in the Year 2000.
26. Li Congresa de la Sociedad Mexicana de urologia: New Advances in Diagnosis and
Treatment of Prostate Cancer, Prognostic factors, November 16, 2000.
27. Li Congresa de la Sociedad Mexicana de urologia: Current Issues in Treatment of
Advanced Prostate Cancer, November 16, 2000.
28. Urology Grand Rounds: Hormonal Strategies in Prostate Cancer. New York Medical
College. April 19, 2001.
29. Urology Grand Rounds: Evidence Based Therapies in Prostate Cancer. Long Island
Medical College. Brooklyn, New York. May 7, 2001.
30. Grand Rounds: State University of New York, Albany, New York. Division of
Urology. “Case Management in Prostate Cancer.” May 2001.
31. Advanced Prostate Cancer Management: Guest Speaker, South Carolina Urological
Association – September 18, 2002.
32. Superficial Bladder Cancer: Guest Speaker, Georgia Urological Association –
September 27, 2002.
33. Management Scenarios for Prostate Cancer: Guest Speaker, Georgia Urological
Association – September 28, 2002.
34. Management Scenarios for Prostate Cancer: Guest Speaker, South Carolina
Urological Association – September 28, 2002.
35. 25th Annual Oncology Update, Cedars Medical Center: Guest Speaker, “Treatment
Options for localized and Advanced Prostate Cancer” – February 21, 2003.
36. Guest Lecture Series: University of Tokushima, Kobe University, Tokyo University,
Nara Medical University. Treatment and Management of Prostate Cancer.
September 7-12, 2003.
37. Management Scenarios for Prostate Cancer: Guest Speaker, South Carolina
Urologic Association, September 2003.
38. Grand Rounds: Baylor Urology Education Department. The Changing Face of
Hormonal Therapy. November 12, 2003.
39. Hormonal Therapy Options for Prostate Cancer. Visiting Professor, Ochsner Clinic,
New Orleans, LA, May 28, 2004.
40. Guest Lecture Series: Tokyo University, Tokyo, Japan. MAB Workshop. July 2,
2004.
41. Visiting Professor: University of Kochi, Kochi, Japan. Hormonal Therapy in Prostate
Cancer. July 3, 2004.
42. Visiting Professor: University of Iwate, Iwate, Japan. Issues in Prostate Cancer.
July 4, 2004.
43. Visiting Professor: University of Yamaguchi, Yamaguchi, Japan. Advanced Prostate
Cancer. July 6, 2004.
44. Grand Rounds: Baptist Memorial Hospital, Columbia, SC. Issues in Hormonal
Therapy. September 30, 2004.
45. Grand Rounds: Management of Refractory Metastatic Prostate Cancer. Panama
City, FL. October 24, 2004.
46. Grand Rounds: Chemotherapy in Prostate Cancer. Valdosta, GA. October 25, 2004.
11
T.KEANE REV 05/27/2010
47. Grand Rounds: Combined Androgen Blockade. Winston-Salem, NC. December 15,
2004.
48. Invited Professorship: Are we “curing” disease?. CURE Workshop, Toronto, Canada.
January 6-8, 2005.
49. Invited Professorship: Imaging and Management of Prostate Cancer. Virginia
Urologic Society. February 12, 2005.
50. Grand Rounds: Perineal Prostatectomy. University of North Carolina. February 25,
2005.
51. Distinguished Visiting Professor: Perineal Prostatectomy. Walter Reed Army
Medical Center, Center for Prostate Disease Research. November 5, 2005.
52. American School of Oncology 3rd Annual Oncology Highlights: Review of Major
Tumor Types. Emory University, Atlanta, GA. July 20 – 21, 2007.
53. International Guest Speaker to Il Central American & Caribbean Prostate Cancer
Summit, Santo Domingo, Dominican Republic, July 30, 2007. Management of
Locally Advanced Disease. PSA Relapse Following Surgery and Radiotherapy –
assessment and treatment options for each.
54. Guest Speaker: John W. Whittington, MD Endowed Lecture: Prostate Cancer.
When Primary Therapy Fails – What Next? And ASCO/AUA Highlights on Prostate
Cancer. University of Tennessee Graduate School of Medicine, November 1 – 2,
2007.
55. Keynote Speaker: British Association of Urological Surgeons Section of Oncology
10th Annual Meeting. Managing Failure of Local Prostate Cancer Treatment and
Perineal Prostatectomy. Bristol, England, November 15 – 16, 2007.
56. Grand Rounds: Prognostic Value of Prostate-Specific Antigen Kinetics in Prostate
Cancer Patients with Biochemical Recurrence. Karmanos Cancer Institute, Detroit,
MI, February 27, 2008.
57. Guest Lecturer: Failure After Definitive Treatment of Prostate Cancer, Georgia
Urological Association Spring Meeting. Medical College of Georgia. February 21 –
24, 2008. Lake Oconee, GA.
58. International Guest Speaker: The National Congress of Urology: Current
Management of Locally Advanced Prostate Cancer; Another Alternative. Nuevo
Leon, Mexico, April 15-19, 2008.
59. Lecture: From Bench to Bedside, Diagnostics and treatment of Prostate Cancer.
Medical University of South Carolina. September 30, 2008. Charleston, South
Carolina.
60. Grand Rounds: Detection of Prostate Cancer. Oregon Health Science University.
June 12, 2009. Portland, Oregon.
61. Grand Rounds: Detection of Prostate Cancer. Hackensack University Medical
Center. November 13, 2009. Hackensack, New Jersey.
62. Guest Speaker: Update on the Treatment of Bladder Cancer. Urology Conference of
West Virginia. May 7, 2010. Charleston, West Virginia.
Presentations to Learned Societies (selected 1993 - present)
1. Society of University Urology Residents, The importance of combination therapy in
effecting cures in advance bladder cancer: An analysis of single agent cisplatin
12
T.KEANE REV 05/27/2010
(DDP) +/- Fluorouracil using an in vivo survival model of human TCC. May 1993.
2. British Association of Urological Surgeons. Impotence following pelvic fracture
urethral distraction defect (PFUDD): Its incidence and the effect of delayed perineal
repair. June 1993
3. Irish Society of Urology. Reverse sandwich therapy for difficult Staghorn calculi.
April 1993.
4. Southeastern Section AUA Meeting. Bropirimine immunotherapy of bladder CIS:
positive phase II results of an oral interferon inducer, March 1994.
5. Southeastern Section AUA Meeting. Fournier’s Gangrene: An improved outlook,
March 1994.
6. Southeastern Section AUA Meeting. Racial differences in prostate cancer trends
since 1980, March 1994.
7. Southeastern Section AUA Meeting. Stage of prostate cancer when detected by PSA
or DRE. March 1994.
8. Southeastern Section AUA Meeting. Does a staging pelvic lymphadenectomy make
a significant difference in the outcome of patients with prostatic adenocarcinoma? ,
March 1994.
9. American Urological Association. Evaluation of Strontium-89 (Sr-89), for palliation
of bone pain in patients with Stage D-2 Adenocarcinoma of the prostate. , May
1994.
10. American Urological Association. Value of prostate specific antigen levels in
detecting recurrences after radical prostatectomy, May 1994.
11. American Urological Association. Priapism: Review of 55 patients treated over the
last eight years at Emory University, May 1994.
12. American Urological Association. Impotence following pelvic fracture with urethral
injury, its incidence, etiology and management, May 1994.
13. American Association for Cancer Research, Inc. Intravesical Dextran for
Chemoprevention of Transitional Cell Carcinoma of the Bladder. March 1995
14. American Association for Cancer Research, Inc. DNA Delivery in Advanced
Androgen Independent Prostate Cancer: Cellular and Nuclear Targeting for Gene
Therapy., March 1995.
15. American Society of Clinical Oncology. CPT-11/Cisplatin: An Effective Preclinical
Combination in The Therapy of Advanced Human Bladder Cancer (TCC) , May,
1995.
16. American Urological Association. Intravesical Dextran for Chemoprevention of
transitional cell carcinoma of the bladder, May 1995.
17. American Urological Association. DNA delivery in advanced androgen independent
prostate cancer: Cellular and nuclear targeting for gene therapy, May 1995.
18. American Urological Association. The significance of platelet counts on survival of
patients with renal cell carcinoma, May 1995.
19. American Urological Association. Intraurethral prostaglandin for the treatment of
post-prostatectomy impotence, May 1995.
20. European Cancer Center Topo. Cisplatin/Camplothecin Analogues: An effective
preclinical treatment in advanced bladder carcinoma, September 1995.
21. American Urological Association. Cytotoxicity of Fumonisin B1 for Renal Cell
Carcinoma and Other Tumor Cell Lines: A New Class of Possible Chemotherapeutic
Agents, May 1996.
13
T.KEANE REV 05/27/2010
22. American Urological Association. Camptothecin Analogues in the Therapy of
Advanced Renal Cell Carcinoma. Results of In Vivo Studies Using a Model of
Human Renal Cell Carcinoma (RCC) , April 1997.
23. American Urological Association. Irenotecan (CPT-11) in Advanced Renal Cell
Carcinoma: Results of a Multi Dose Study Defining the Minimal Effective Dose
Using a Model of Advanced Renal Cell Carcinoma (RCC) , May 1998.
24. American Urological Association. Establishment of a New Renal Orthotopic and
Metastatic Human Tumor Model, May 1999.
25. British Association of Urologic Surgeon. Female Cystectomy and Options for
Diversion. Post graduate course, June 1999.
26. American Urological Association. 9-Amino Camptothecin (9-AC): An Effective
Therapy in an Animal Model of Human Metastatic Renal Cell Carcinoma (RCC) ,
May 2000.
27. American Urological Association. 9-Amino Camptothecin (9-AC): An Effective
Therapy Against a Pre-clinical in Vivo Model of Human Prostatic Cancer, May 2000.
28. American Urological Association. Biotechnology Forum. The Use of Positron
Emission Tomography in Urology, May 2000.
29. British Association of Urologic Surgeons. Prostate Cancer Challenge. UK vs. USA:
Captain USA Team, June 20, 2000.
30. American Urological Association. Prognostic Role of CD44 Cell Adhesion Molecule
Protein Expression in Primary and Metastatic Renal Cell Carcinoma (RCC): A
Clinical Pathologic Study of 125 Cases, May 2001.
31. Presentation at Southeast Section/AUA. Combination Intravesical Immunotherapy
(BCG Plus Interferon x-2B) in High Grade Recurrent Superficial Transitional Cell
Carcinoma. TE Keane, SM Eldaieef, HS Clarke, PP Daily.
32. British Association of Urological Surgeons. The Use of Intestine in Reconstructing
or Replacing the Urinary Tract. Guest Professor, June 2003.
33. Richmond Urological Forum. Hormone Refractory Prostate Cancer and Hormone
Therapy, October 11, 2003.
34. Southern Society of Urological Surgeons, October 2003.
35. Horger DC, McRacken D, Keane TE. Correlation of PSA velocity with prostascint
finding of metastatic prostate cancer following radical prostatectomy. Poster
presentation at Southeastern AUA section meeting, March 2004.
36. Reeves HM, Horger DC, Wolff DJ, Keane TE. Effects of intravesical therapy on the
flourescent in situ hybridization assay. Podium presentation at Southeastern AUA
section meeting, March 2004.
37. Horger DC, Sudarshan S, Daily PP, Clarke HS, Keane TE. Laparoscopic Renal
Cryoablation. Video presentation at Southeastern AUA section meeting, March
2004.
38. Wingo MS, Corica F, Maffie NL, Keane TE. Effect of antibiotic therapy in patients
with increasing prostate specific antigen and/or abnormal digital rectal exam.
Presentation at Southeastern Section AUA meeting, March 2004.
39. Wingo MS, Corica F, Keane TE. Effect of antibiotic therapy in patients with prostate
specific antigen between 4-10 NG/ML. Podium presentation at Southeastern
section AUA, March 2004.
40. Sudarshan S*, Holman DH, Hyer ML, Keane TE, Norris JS. In vitro efficacy of Fas
Ligand gene therapy for the treatment of bladder cancer. Presented for the 2003
14
T.KEANE REV 05/27/2010
Montague Boyd Essay Contest. Presentation at the annual meeting of the
American Urological Association, 2004.
41. Sudarshan S*, Elzawahry A, Keane TE, Norris JS. Assessment of in vitro efficacy
of Fas Ligand gene therapy against ACHN renal cell carcinoma line. Presentation
at the annual meeting of the American Urological Association, 2004.
42. Carson C, Guay A, Keane T, McCullough A, Miner M, Morgentaler A, Notman D,
Rosen R, Shabsigh R, Spark R. Optimizing testosterone replacement therapy in
hypogonadal men. Roundtable discussion at the annual meeting of the American
Urological Association, 2006. Published in Contemporary Urology, May 2007.
43. Bong GW, Hooper HB, Parker RO, Harty N, Keane TE. Variability of Pathologist
Evaluating Surgical Margins May Impact Patient Care After Radical Prostatectomy.
Presentation at the American Urological Association Annual Meeting. May 2007.
44. Ayman E Mahdy, MD, Xiang Liu, MD, PhD, Joe Cheng, BS, Ahmed M Elzawahry,
MD, Lorianne S Turner, PhD, Antonio F Saad, MD, Saeed Elojeimy, BS, Yusuf A
Hannun, MD, PhD, Thomas E Keane, MD, Mohammed Taha, MD, Hisham M
Hammouda, MD, James S Norris, PhD. Radiation therapy upregulates coxsackieadenovirus receptor in prostate cancer cells and sensitizes prostate cancer to fas
ligand gene therapy. Presentation at the American Urological Association Annual
Meeting, May 2007.
45. Ayman E Mahdy, MD, Xiang Liu, MD, PhD, Youssef Zeidan, BS, Ahmed M
Elzawahry, MD, Joe Cheng, BS, Alecia Bielawska, PhD, Yusuf A Hannun, MD,
PhD, Thomas E Keane, MD, Mohammed Taha, MD, Hisham M Hammouda, MD,
James S Norris, MD. Acid Ceramidase Upregulation in response to prostate cancer
radiotherapy: A target for radio-sensitization. Presentation at the American
Urological Association Annual Meeting, May 2007.
46. Keane T, Margin Status as a Predictor of Outcome Post-Prostatectomy, Southern
Society of Urologic Surgeons Annual Meeting, October 14 – 17, 2007.
47. Chaudhary UB, Gudena V, Clarke HS, Savage SJ, Curry N, Wahlquist A, Keane T.
A phase II trial of gemcitabine and irinotecan in patients with metastatic bladder
cancer. Poster presentation at American Society of Clinical Oncology 2008 GU
Cancers Symposium, February 2008.
48. El-Zawahry AM, Springer J, Wingo MS, Clarke HS, Keane TE. Effect of long term
antibiotic therapy on patients with PSA 4.1 -10 ng/ml with biopsy-proven
asymptomatic prostatitis. Poster presentation at American Society of Clinical
Oncology 2008 GU Cancers Symposium, February 2008.
49. Bong G, Hamilton JN, Clarke JC, Clarke HS, Keane TE. The Effect of Obesity and
Age on Early Mortality Rish After Radical Cystectomy for Bladder Cancer.
Presented at the Southeastern Section of the American Urological Association,
March 8, 2008.
50. Yoost T, Clarke HS, Doyle KE, Keane TE, Savage SJ. Laparoscopic Cryoablation of
Renal Masses: Which Lesions Fail?. Poster presentation at Southeastern Section of
American Urologic Association, March 6, 2008.
51. Mahdy A, Liu X, Li J, Elojeimy S, Cheng J, Turner L, Bai A, El-Zawahry AM,
Bielawska A, Hannun YA, Keane TE, Taha MI, Hammouda HH, Norris JS.
Inhibition of acid ceramidase sensitizes prostate cancer to radiation therapy both
in vitro and in vivo. Presentation to the American Urological Association Annual
Meeting, May 2008.
15
T.KEANE REV 05/27/2010
52. Ramsey SD, Zeliadt SB, Moinpour CM, Hall IJ, Lee JW, Ekwueme DU, Thompson
IM, Keane TE, Fedorenko CR, Penson DF. Provider Encourgaement of Shared
Decision Making Among Newly Diagnosed Patients with Local Stage Prostate
Cancer. Presentation at the 30th Annual Meeting of the Society for Medical Decision
Making, Philadelphia, Pennsylvania. October 18-22, 2008.
53. Ramsey SD, Zeliadt SB, Moinpour CM, Hall IJ, Lee JW, Ekwueme DU, Thompson
IM, Keane TE, Fedorenko CR, Penson DF. Race and Shared Decision Making
Among prostate Cancer Patients, Family Members and Physicians. Presentation to
International Society for Quality of Life Research 15th Annual Scientific Meeting,
Montevideo, Uruguay. October 22-25, 2008.
54. Ramsey SD, Zeliadt SB, Moinpour CM,Hall IJ, Lee JW, Ekwueme DU, Thompson
IM, Keane TE, Fedorenko CR, Penson DF. Race and Shared Decision Making
Among Prostate Cancer Patients, Family Members and Physicians. Presentation to
ISPOOR 11th Annual European Congress, Athens, Greece. November 10, 2008.
55. Ramsey SD, Zeliadt SB, Blough DK, Fedorenko CR, Moinpour CM, Hall IJ, Lee
Smith J, Ekwueme DU, Fairweather ME, Thompson IM, Keane TE, Penson DF. A
comparison of physician and patient decision making for first versus second
opinions among men with local stage prostate cancer. International Society for
Pharmacoeconomics and Outcomes Research (ISPOR) 15th Annual International
Meeting. 2010 May 15-19; Atlanta, GA.
56. Keane TE, El-Zawahry AM. Selection of Patients for Salvage cryosurgical ablation of
the Prostate Utilizing fused Capromab Pendetide Scanning. European Association
of Urology 25th Annual Congress Meeting. 2010 April 16-20; Barcelona, Spain.
Bibliography:
Publications
1. T. Keane, J. Bourke, B. Maurer. Spontaneous Mitral Valve Rupture in a Normal
Heart.Irish Medical Journal 76:423-424, 1983.
2. J. Bourke, T. Keane, B. Maurer. Infective Endocarditis - A Review of 19 Patients.
Irish Journal of Medical Science 154(7):262-269, 1985.
3. T. E. Keane, B. Lane, D. P. O'Donoghue, J. M. P. Hyland. Adenocarcinoma
Complicating Crohn's Disease at Initial Presentation. Irish Journal of Medical
Science 155(12):439-440, 1986.
4. J. A. Heaney, M. Allen, T. E. Keane, M. J. Duffy. Prostate Specific Antigen:
Superior Serum Marker for Prostatic Carcinoma. Irish Journal of Medical Science
156(5):138,1987.
5. T. E. Keane, D. G. Kelly. Bilateral Obstructed Ectopic Duplex Ureters. British
Journal of Urology 60(3): 82-3, 1987.
6. T. E. Keane, R. J. Fitzgerald. Duplicated Blind Ending Ureter. British Journal of
Urology 60(3): 275, 1987.
7. D. J. Barton, T. N. Walsh, T. E. Keane, J. P. Duignan. Malignant Duodeno-Colic
Fistula: Report of a Case and Review of the Literature. Diseases of the Colon and
Rectum 30(8):636-7, 1987.
8. T. E. Keane, B. Dillon, N. H. Afdhal, C. J. McCormack. Conservative Management
of Perforated Duodenal Ulcer. British Journal of Surgery 75:583-4, 1988.
16
T.KEANE REV 05/27/2010
9. T. E. Keane, P. Tait, A. L. G. Peel, A. R. Tanner. Profuse Rectal Bleeding: An
Unusual Cause Diseases of the Colon and Rectum 31(12):989-990, 1988.
10. T.E. Keane, J.T. Donaldson, P.J. Walther. In vivo preclinical assessment of
potentially synergistic cytotoxic therapeutic strategies in human bladder
carcinoma. Surgical Forum 40:692-4, 1989.
11. J.T. Donaldson, T.E. Keane, S.H. Poulton, P.J. Walther. Enhanced in vivo
cytotoxicity of recombinant human tumor necrosis factor with etoposide in human
renal cell carcinoma: Evaluation in a preclinical model. Urology Research 18(4):
245-50, 1990.
12. P.J. Walther, J.T. Donaldson, T.E. Keane. An in vivo preclinical study of
enhancement by etoposide of the cytoreductive antitumor effect of recombinant
human tumor necrosis factor in the treatment of human renal carcinoma. In: New
Trends in Diagnosis and Treatment of Renal Cancer. Urologic Oncology (L.
Giuliani, F. Boccardo, L. Santi, D. Pescatore, Eds.) Acta Medica, Edizioni e
Congressi, Toma, 1991, pp. 49-57.
13. J.T. Donaldson, J.A. Tucker, T.E. Keane, P.J. Walther, K.S. Webb.
Characterization of a new model of human metastatic cancer of the prostate: The
multicellular tumor spheroid. International Journal Cancer 46:238-244, 1990.
14. T.E. Keane, G. Rosner, J.T. Donaldson, D.L. Norwood, S.H. Poulton, P.J. Walther.
Dipyridamole - Cisplatin potentiation: Enhanced in vivo cytotoxicity in xenograft
models of human testicular and bladder cancer. Journal of Urology 144:10041009, 1990.
15. T.E. Keane, A.L.G. Peel. Endometrioma: an intra-abdominal troublemaker.
Diseases of the Colon and Rectum 33(11): 963-965, 1990.
16. S. Nicholson, T.E. Keane, H.B. Devlin. Femoral Hernia: a continuing source of
available mortality. British Journal of Surgery 77(3): 307-308, 1990.
17. T.E. Keane, J.R. Gingrich, G. Rosner, P.J. Walther. Preclinical in vivo assessment
of 5-Fluorouracil/Cisplatin with and without Dipyridamole against a human
bladder tumor line: Correlation of tumor growth inhibition with host survival.
Surgical Forum 41:696-8, 1990.
18. R.P. Kaufman, T.E. Keane, J.A. Tucker, H.B. Hechtman, P.J. Walther. A
pharmacologically induced increased plasma prostacyclin to thromboxane A2) ratio
protects the testis from ischemic necrosis. Surgical Forum 41:713-5, 1990.
19. T.E. Keane, P.J. Walther. Multimodal therapy in germinal cell testicular cancer:
stage-specific algorithms of management. Infections in Urology (Jan. 1991)
20. T.E. Keane, G. Rosner, J.R. Gingrich, S.H. Poulton, P.J. Walther. The therapeutic
impact of Dipyridamole: Chemopotentiation of the cytotoxic combination 5Fluorouracil/Cisplatin in an animal model of human bladder cancer. Journal of
Urology 146:1418-1424, 1991.
21. J.R. Gingrich, T.E. Keane, P.J. Walther. In vivo cisplatin and carboplatin
chemosensitization by dipyridamole: Differential impact on efficacy/toxicity
(therapeutic index) against human bladder and testicular carcinoma. Surgical
Forum 1991.
22. T.E. Keane. Circumcision: New indications in the 1990's? Current Opinion in
Urology, Jan. 1992.
23. J.L. Weinerth, T.E. Keane, C.C. Carson. Shockwave lithotripsy: Initial therapy
prior to nephrostolithotomy in selected patients. J Endourology 6: No. 1, 1992,
17
T.KEANE REV 05/27/2010
pp.15-18.
24. J.A. Fernandez, T.E. Keane, W.S. Weems, C.C. Carson. The use of a protective
plastic sheath for prostate biopsy. Urology January 1993.
25. J. Geoghegan, T.E. Keane, A.L.G. Peel, H.B. Devlin. Gastric carcinoma: Treatment
and results in a district general hospital. J Roy Col Surg Edin, August 1993.
26. T.E. Keane, G. Rosner, P.J. Walther. Combination versus single agent therapy
effecting complete therapeutic response in human bladder cancer: Analysis of
cisplatin and/or 5-Fluorouracil in an in vivo survival model. Cancer Research: 54.
475-481, January 1994.
27. TE Keane, JA Petros, B Velimirovich, K To Yue, SD Graham, Jr. Methoxypsoralen
Phototherapy of Transitional Cell Carcinoma. Urology; 44(6), 842-846, 1994.
28. Keane, T.E., Smith, E.A. The Surgical Management of Renal Cell Carcinoma with
Caval Extension. Problems in Urology, 1994, 8 (4), 551-562.
18
T.KEANE REV 05/27/2010
29. Keane, TE, Petros, JA, Clarke, HS, Dillehay, DL, Kassabian, VS, Oladele, A,
Napalkov, P, Graham, SD. Intravesical Suramin in the Prevention of Transitional
Cell Carcinoma. Urology, 45(1):59-63, 1995.
30. Keane, TE, Graham, Jr, SD. Conservative Renal Surgery / has it a role in Renal
Cell Carcinoma? Surgical Oncology Clinics of North America; 4(2): 295-306, 1995.
31. El-Galley, RES, Petros, JA, Sanders, WH, Keane, TE, Galloway, NTM, Cooner, WH,
Graham Jr., SD. Normal Range Prostate-Specific Antigen vs. Age-Specific
Prostate-Specific Antigen in Screening Prostate Adenocarcinoma. Urology; 46:2,
1995.
32. Mark, S.D., Keane, T.E., Vandemark, R.M., Webster, G.D. Impotence Following
Pelvic Fracture Urethral Injury; Incidence, Aetiology and Management. British
Journal of Urology, 1995, 75, 62-64.
33. Graham, Jr., S.D., Keane, T.E., Petros, J.A., Sanders, W.H. Perioperative
Hormonal Therapy in Locally Advanced Adenocarcinoma of the Prostate. Cancer,
1995, 75 (7), Suppl.1969-1971.
34. Fisher AH. Wallace VL. Keane TE. Clarke HS. Two cases of vasculitis of the
urinary bladder: diagnostic and pathogenetic considerations. Archives of Pathology
& Laboratory Medicine. 122(10):903-6, 1998 Oct.
35. El-Galley RE. Keane TE. Petros JA. Sanders WH. Clarke HS. Cotsonis GA. Graham
SD Jr. Evaluation of staging lymphadenectomy in prostate cancer. Urology.
52(4):663-7, 1998 Oct.
36. Keane TE, El-Galley RE. Sun C. Petros JA. Dillahey D. Gomaa A. Graham SD Jr.
McGuire WP 3rd. Camptothecin analogues/cisplatin: an effective treatment of
advanced bladder cancer in a preclinical in vivo model system. Journal of Urology.
160(1):252-6, 1998 Jul.
37. Jiminez RE. Keane TE. Hardy HT. Amin MB. PT1 urothelial carcinoma of the
bladder: Criteria for diagnosis, pitfalls, and clinical implications. Advances in
Anatomic Pathology. 7(1):13-25, 2000 Jan.
38. El-Galley RE. Keane TE. Embryology, anatomy, and surgical applications of the
kidney and ureter. Surgical Clinics of North America. 80(1381-401, xiv, 2000 Feb.
39. Symbas NP. Townsend MF. El-Galley R. Keane TE. Graham SD. Petros JA. Poor
prognosis associated with thrombocytosis in patients with renal cell carcinoma.
BJU International 86(3):03-7, 2000 Aug.
40. Desai, D, Lim, SD, Jiminez, RE, Chun, T, Keane, TE, McKenney, JK, ZavalaPompa, A, Cohen, C, Young, RH, Amin, MB: Relationship of Cytokeratin 20 and
CD44 Protein Expression with WHO/ISUP Grade in pTa and pT1 Papillary
Urothelial Neoplasia. Modern Pathology. 13 (12):1315-1323, 2000.
41. La Fata V, Ramachandran A, Galt R, Keane TE, Halkar R.. Diuretic Renogram in a
Patient with a Urinary Diversion: Avoiding a False-Positive Diagnosis of
Obstruction with an indwelling catheter. Clinical Nuclear Medicine, 26 (7) 2001.
42. Perez-Brayfield M, Keane TE, Krishnan A, LaFontaine P, Feliciano D, Clarke H.
Gun Shot Wounds to the Ureter: A 40 Year Experience at Grady Memorial Hospital.
Journal of Urology, July 2001.
43. Keane TE, El-Galley R. Long Term Efficacy of Viagra Tachyphylaxis. Journal of
Urology, September 2001.
44. Chodak GW, Keane T, Klotz L. Critical Evaluation of Hormonal Therapy for
Carcinoma of the Prostate. Urology. 60(2): 201-8. Aug 2002.
19
T.KEANE REV 05/27/2010
45. El-Galley R, Keane T. Orthotopic Neobladder. AUA Update Series, Lesson 36,
Volume XXII.
20
T.KEANE REV 05/27/2010
46. El-Galley R, Keane TE, Sun C. Camptothecin analogues and vinblastine in the
treatment of renal cell carcinoma: an in vivo study using a human orthotopic renal
cancer xenograft. Urol Oncol. 2003 Jan-Feb; 21(1): 49-57
47. Lin PH, Terramani TT, Bush RL, Keane TE, Moore RG, Lumsden AB. Concomitant
Intraoperative Renal Artery Embolization and Resection of Complex Renal
Carcinoma. J Vascular Surgery. 38(3):446-50. September 2003.
48. Bissada NK, Keane T, Caczmarek AT, Zawahry AE, Fahmy WE, Bissada MA,
Yakout HH. Experience with coapted gastric tube outlet and composite
gastrointestinal reservoir for continent cutaneous urinary diversion. J Urology Vol
171,229-31, January 2004.
49. Lendvay TS, Scott DL, Chan DY., Cameron DE, Keane TE, Vega JD, Clarke HS,
Amin M, Marshall FF. Diagnosis And Management Of Renal Cell Carcinoma With
Pulmonary Artery Tumor Emboli. J Urology, 2004.
50. Schinazi F, Hurwitz SJ, Liberman I, Glazkova Y, Mourier NS, Olson J, Keane T.
Tissue Disposition of 5-o-Carboranyluracil – A Novel Agent for the Boron Neutron
Capture Therapy of Prostate Cancer. Nucleosides, Nucleotides & Neucleic Acids.
Vol. 23, Nos. 1 & 2, pp. 291-306, 2004.
51. Chaudhary UB, Keane TE. PC-SPES withdrawal response. Acta Oncology.
2004;43(8):772-3.
52. Norris JS, Norris KL, Holman DH, El-Zawahry A, Keane TE, Dong JY, Tavassoli M.
The present and future for gene and viral therapy of directly accessible prostate
and squamous cell cancers of the head and neck. Future Oncology. 2005
February; 1(1): 115-23.
53. Baker SD, Horger DC, Keane TE. Comminity-acquired methicillin-resistant
Staphylococcus aureus prostatic abscess. Urology. 2004 October;64(4):808-10.
54. Corica FA, Keane TE. Bladder Cancer - Resection/Ablation. Surgical Oncology
Clinics of North America. 2005 April;14(2): 321-52.
55. El-Zawahry, David Holman, Xiang Lue, Saeed Eloyeimy, Nabil Bissada, Hashim
Rashwan, Alicjia Bielwaska, Yusuf Hunnun, James Norris, Thomas Keane.
Lysosomotripic Ceramide Analogue LCL-204, Acid Ceramidase (AC) Inhibitor, A
Potential Novel Chemotherapy for Prostate Cancer. Journal of Urology. May 2005.
56. Horger DC, Wingo MS, Keane TE. Partial segmental thrombosis of corpus
cavernosum: case report and review of world literature. Urology. 2005 July;66(1):
194.
57. Laudadio, J, Keane, T., Reeves, H.M., Savage, S., Hoda, R., Lage, J., Wolff, D.
Fluorescence in situ hybridization for detecting transitional cell carcinoma:
implications for clinical practice. BJU International 96(9), 1282 – 1285. December
2005.
58. Keane TE, Wingo MS, McLeod DG. The Evolving Role of Imaging in Identification
and Management of Prostate Cancer. Reviews in Urology. 2006. Vol. 8 Suppl. 1.
59. Sawhney R, Chaudhary UB, Keane TE. Palliative Care Aspects in the Management
of Advanced Prostate Cancer. Touch Briefings US Genito-Urinary Disease, pages
25 - 27. 2006.
60. Liu X, Elojeimy S, El-Zawahry AM, Holman DH, Bielawska A, Bielawski J,
Rubinchik S, Guo GW, Dong JY, Keane TE, Hannun YA, Tavassoli M, Norris JS.
Modulation of Ceramide Metabolism Enhances Viral Protein Apoptin’s Cytotoxicity
in Prostate Cancer. Molecular Therapy Vol. 14, Pages 637 – 646. November 2006.
21
T.KEANE REV 05/27/2010
61. Norris J, Norris KL, Holman DH, El-Zawahry A, Keane TE, Dong J, Tavassoli M.
The Present and Future for Gene and Viral Therapy of Directly Accessible Prostate
and Squamous Cell Cancers of the Head and Neck. Future Oncology, February
2005 Vol. 1, No. 1, Pages 115 - 123.
62. Liu X, Zeidan YH, Elojeimy S, Holman DH, El-Zawahry AM, Guo G, Bielawska A,
Szulc Z, Rubinchik S, Dong JY, Keane TE, Tavassoli M, Hannun YA, Norris JS.
Involvement of Sphingolipids in Apoptin-Induced Cell Killing. Molecular Therapy
Vol. 14, Pages 627 - 636 November 2006.
63. T. Keane, D. Gillatt, C. Lawton, H. Payne, B. Tombal. Treatment Options in
Prostate Cancer Once Primary Therapy Fails. European Urology
Supplements, Volume 6, Issue 3, Pages 344-353 November 2006.
64. T. Keane, D. Gillatt, C. Evans, A. Tubaro. Current and Future Trends in the
Treatment of Renal Cancer?. European Urology Supplements, Volume 6, Issue 3,
Pages 374-384 November 2006.
65. O. Moussa, H. Abot-Enein, N. Bissada, T. Keane, M.A. Ghoneim, D. Watson.
Evaluation of Survivin Reverse Transcriptase-Polymerase Chain Reaction for
Noninvasive Detection of Bladder Cancer. Journal of Urology, Volume 175, 23122316, June 2006.
66. H. VanPoppel, L. DaPozzo, W. Albrecht, V. Matveev, A. Bono, A. Borkowski, J-M
Marechal, L. Klotz, E. Skinner, T. Keane, I Claessens, R. Sylvester. A Prospective
Randomized EORTC Intergroup Phase 3 Study Comparing the Complications of
Elective Nephron-Sparing Surgery and Radical Nephrectomy for Low-Stage Renal
Cell Carcinoma. European Urology 51 (2007) 1606-1615.
67. T. Keane, I.L. Rosner, M.S. Wingo, D.G. McLeod. The Emergence of
Radioimmunoscintigraphy for Prostate Cancer. Rev Urol. 2006;8 Suppl 1:S20-8.
68. B. E. Drake, T.E. Keane, C.M. Mosley, S.A. Adams, K.T. Elder, M. V. Modayil, J.R.
Ureda, J.R. Hebert. Prostate Cancer Disparities in South Carolina: early detection,
special programs, and descriptive epidemiology. JSC Med Assoc. 2006 Aug;102(7):
241-9.
69. David Gillatt, Thomas Keane, Kurt Miller. Challenges in the Management of
Urological Cancers. European Urology Supplements, European Association of
Urology, Volume 6 Issue 3 2007 March.
70. N. Fleshner, TE Keane, CA Lawton, PF Mulders, H. Payne, SS Taneja and T. Morris.
Adjuvant Androgen DeprivationTtherapy Augments Cure and Long-term Cancer
Control in Men with Poor Prognosis, Nonmetastatic Prostate Cancer. Prostate
Cancer and Prostatic Diseases. 2007July (3):1-7.
71. A.F. Saad, W.D.Meacham, A. Bai, V. Anelli, S. Elojeimy, A.E. Mahdy, L.S. Turner,
J. Cheng, A. Bielawska, J. Bielawska, T.E. Keane, L.M. Obeid, Y.A. Hannun, J.S.
Norris, X. Liu. The Functional Effects of Acid Ceramidase Overexpression in
Prostate Cancer Progression and Resistance to Chemotherapy. Cancer Biol Ther.
2007 Sep;6(9):1455-60.
72. S.J. Savage, M.S. Wingo, H.B. Hooper, M.T. Smith, T.E. Keane. Pathologically
Confirmed Port Site Metastasis After Laparoscopic Radical Prostatectomy: Case
report and literature review. Urology. 2007 Dec;70(6):1222 e9-11.
73. G.W. Bong, T.E. Keane. Salvage Options for Biochemical Recurrence After Primary
Therapy for Prostate Cancer. Can J Urol. 2007 Dec;14 Suppl 1:2-9.
22
T.KEANE REV 05/27/2010
74. H.S. Clarke, M.R. Eskridge, A.M. El-Zawahry, T.E. Keane. Salvage Cryosurgical
Ablation of the Prostate for Local Recurrence After Radiation Therapy: Improved
outcomes utilizing a capromab pendetide scan and biopsy algorithm. Can J Urol.
2007 Dec; 14 Suppl 1:24-7.
75. M.L. Ramirez, T.E. Keane, C.P. Evans. Managing Prostate Cancer: The role of
hormone therapy. Can J Urol. 2007 Dec; 14 Suppl 1:10 – 8.
76. G.W. Bong, H.S. Clarke, W.C. Hancock, T.E. Keane. Serum Testosterone Recovery
After Cessation of Long-Term Luteinizing Hormone-Releasing Agonist in Patients
with Prostate Cancer. Urology. 2008 Jun;71(6):1177-80. Epub 2008 Feb 15.
77. G.W. Bong, T.E. Keane. Emerging Role of HIFU as a Noninvasive Ablative Method
to Treat Localized Prostate Cancer. Oncology. Vol. 22 No. 2. Pages 17-19. 2008.
78. Grossman HB, O’Donnell MA, Cookson MS, Greenberg RE, Keane TE. Bacillus
calmette-guerin failures and beyond: contemporary management of non-muscleinvasive bladder cancer. Rev. Urology. 2008 Fall;10(4):281-9.
79. G.W. Bong, T.E. Keane, T.R. Yoost. Perineal Prostatectomy in the Age of Minimally
Invasive Surgery. J. Arkansas Medical Society. 2008 Sep;105(3):67-8.
80. Varela JC, Atkinso C, Woolson R, Keane TE, Tomlinso S. Upregulated Expression of
Complement Inhibitory Proteins on Bladder Cancer Cells and Anti-MUC1 Antibody
Immune Selection. International Journal Cancer. 2008 Sep 15;123(6):1357-63.
81. Bong GW, Ritenour CW, Osunkoya AO, Smith MT, Keane TE. Evaluation of Modern
Pathological criteria for Positive Margins in Radical Prostatectomy Specimens and
their use for Predicting Biochemical Recurrence. BJU International. 2009
Feb;103(3):67-8.
81.Mahdy AE, Cheng JC, Li J, Elojeimy S, Meacham WD, Turner LS, Bai A, Gault CR,
McPherson AS, Garcia N, Beckham TH, Saad A, Bielawska A, Bielawski J, Hannun
YA, Keane TE, Taha MI, Hammouda HM, Norris JS, Liu X. Acid Ceramidase
upregulation in Prostate Cancer Cells Confers Resistance to radiation: AC
inhibition, a potential Radiosensitizer. Mol. Ther. 2009 Mar;17(3):430-8.
Book chapters:
1. Keane, T.E. Carcinoma of the Testis. In: Hurst JW, ed. Medicine for the Practicing
Physician, 4th ed., Connecticut: Appleton & Lange, 1996.
2. Keane, T.E. Epididymitis. In: Hurst JW, ed. Medicine for the Practicing Physician,
4th ed., Connecticut: Appleton & Lange, 1996.
3. Keane, T.E. Endoscopic Approaches to the Kidney and Upper Urinary Tract. In:
James Toouli, Dominique Gossto and John Hunter, eds. Endosurgery.
London/New York: Churchill Livingstone. 847-868, 1996.
4. Keane, T.E. Section Editor (Adrenal) In: Sam Graham, Jr., ed. Glenn’s Urologic
Surgery, 5th edition. Philadelphia: Lippincott-Raven, 1998, pp 3-37.
5. Keane, Thomas E., Santamaria, P.J., Issa, M.M. Pheochromocytoma. In: Sam D.
Graham, Jr. and James F. Glenn, eds. Glenn’s Urologic Surgery, 5th ed., Section
XIV, “Frontiers”, Philadelphia: Lippincott-Raven, 1998:27-37.
6. Issa, Muta M., and Keane, Thomas E. Adrenal Adenoma and Carcinoma. In: Sam
D. Graham, Jr. and James F. Glenn, eds. Glenn’s Urologic Surgery, 5th ed., Section
XIV, “Frontiers”, Philadelphia: Lippincott-Raven, 1998:9-17.
23
T.KEANE REV 05/27/2010
7. El-Galley, Rizk and Keane, T.E. Kidneys, Ureters and Bladder. In: William C.
Wood and John E. Skandalakis, eds. The Anatomic Basis of Tumor Surgery. St.
Louis, Mo.: Quality Medical Publishing, 1999, 825-871.
8. Keane, T.E., Gomella L.G., Dambro W.L. Adenocarcinoma of the Bladder. In: Five
Minute Urology Consult. Lippincott, Williams & Wilkins. 2000.
9. Keane, T.E. , Co-Editor, Glenn’s Urologic Surgery, 6th edition. Lippincott Williams
& Wilkins, 2004.
10. Keane, T.E., Co-Editor, Glenn’s Urologic Surgery, 7th edition. Lippincott Williams &
Wilkins, 2008.
Book reviews:
Hernia Repair Without Disability (2nd ed)
I. L. Lichtenstein. Ishiysku Euro-America Inc. 1987
T. E. Keane, S. Nicholson.
World Journal of Surgery 12(3): 424, 1988.
Other publications:
Abstracts (selected)
1. T. E. Keane, B. Dillon, N. H. Afdhal, C. J. McCormack. Conservative Management
of Perforated Duodenal Ulcer - A Retrospective Review. Irish Journal of Medical
Science 156(5):161 (abst), 1987.
2. T. E. Keane, J. Geoghegan, I. L. Rosenberg, A. W. Dellipiani, A. L. G. Peel. Gastric
Carcinoma: A 5-Year Review in a District General Hospital. European Journal of
Surgical Oncology 14(6):713 (abst), 1988.
3. T. E. Keane, S. H. Poulton, P. J. Walther. Methotrexate based cytotoxic
combinations in human bladder cancer: Preclinical evaluation of potential in vivo
synergism in an animal host. J of Urology 141:874 (abst 386), 1989.
4. J.T. Donaldson, T.E. Keane, P.J. Walther. Therapeutic synergism of recombinant
tumor necrosis factor and Etoposide in the treatment of human renal carcinoma:
Preclinical assessment of efficacy by in vivo subrenal capsule assay. Proceedings of
the American Society of Clinical Oncology 8:193 (abst 752), 1989.
5. J.T. Donaldson, T.E. Keane, P. Chai, P.J. Walther, K.S. Webb. Development of a
multicellular tumor spheroid system from a metastatic human prostate carcinoma
cell line. Proceedings of the American Association for Cancer Research 30:608 (abst
2419), 1989.
6. T.E. Keane, G. Rosner, P.J. Walther. Dipyridamole - an in vivo chemosensitizer of
cisplatin and etoposide cytotoxicity in nude mouse models of human bladder and
testicular cancers. Proceedings of the American Society of Clinical Oncology 9:56
(abst 216), 1990.
7. T.E. Keane, G. Rosner, P.J. Walther. Modulation of Vinblastine cytotoxicity by
Dipyridamole versus Tamoxifen: an in vivo preclinical study by subrenal capsule
assay of human renal carcinoma. Proceedings of the American Association for
24
T.KEANE REV 05/27/2010
Cancer Research 31:376 (abst 2230), 1990.
25
T.KEANE REV 05/27/2010
8. T.E. Keane, J.A. Tucker, K.S. Webb, P.J. Walther. Dipyridamole enhancement of
in-vivo Cisplatin cytotoxicity: evidence for chemosensitization in a new human
germ cell (testicular) embryonal carcinoma xenograft tumor line. Journal of Urology
143(4):264 (abst 304), 1990.
9. T.E. Keane, J.R. Gingrich, G. Rosner, P.J. Walther. Dipyridamole - a new
chemosensitizer of 5-Fluorouracil and Cisplatin enhanced in vivo cytotoxicity in an
animal model of human transitional cell (bladder) carcinoma Journal of Urology
143(4):274 (abst 341), 1990.
10. P.J. Walther, T.E. Keane. Treatment of metastatic hormone-refractory prostate
carcinoma with Cisplatin and continuous infusion 5-Fluorouracil. Journal of
Urology 143(4):308 (abst 680), 1990.
11. R. Kaufman, T.E. Keane, P.J. Walther. Acute testicular ischsemia: pharmacologic
reduction of reperfusion injury by prostanoid modulation. Journal of Urology
143(4):262 (abst 295), 1990.
12. J.R. Gingrich, T.E. Keane, P.J. Walther. Disparate in vivo impact of the
chemosensitizer dipyridamole on the therapeutic index of cisplatin, carboplatin and
etoposide: A preclinical evaluation in a human bladder cancer xenograft model.
Proc Am Assoc Ca Res 32:374, 1991. (abst 2223)
13. Smith E, Clarke HS, Keane TE, Petros JA, Graham Jr. SD, Taylor A. Evaluation of
strontium-89 (Sr-89) for palliation of bone pain in patients with stage D2
adenocarcinoma of the prostate.
J. Urol, 151(5): 239A Abstract 46, 1994.
14. Hale BD, Kaplan CR, Keane TE, Petros JA, Graham Jr. SD. Value of prostate
specific antigen levels in detecting recurrences after radical prostatectomy. J. Urol,
151(5): 257A Abstract 118, 1994.
15. Todd H. Hoekstra, Michael A. Witt, Niall TM Galloway, Thomas E. Keane. Priapism:
Review of 55 Patients Treated over the Last Eight Years at Emory University. J.
Urol, 151(5):308A Abstract 322, 1994.
16. George D. Webster, Stephen D. Mark, Thomas E. Keane, R. Vandermark.
Impotence Following Pelvic Fracture with Urethral Injury, its incidence, etiology
and Management. J. Urol, 151(5):358A Abstract 522, 1994.
17. Adams, JB, Sarosdy, MF, Keane TE, Petros JA, Graham, Jr, SD. Bropirimine
immunotherapy of bladder CIS: positive phase II results of an oral interferon
inducer. Southeastern Section AUA Meeting, 1994.
18. Adams, JB, Keane, TE, Petros, JA, O'Brien, DP, Galloway, NTM, Graham, Jr, SD.
Fournier's Gangrene: An Improved Outlook. Southeastern Section AUA Meeting,
1994.
19. Keane, TE, Anderson, CC, Liff, JA, Petros, JA, Graham, Jr., SD. Racial differences
in prostate cancer trends since 1980. Southeastern Section AUA Meeting, 1994.
20. Heron, SP, Petros, JA, Keane, TE, Graham, Jr, SD. Stage of prostate cancer when
detected by PSA or DRE. Southeastern Section AUA Meeting, 1994.
21. Heron, SP, LaFontaine, PD, Keane, TE, Petros, JA, Galloway, NTM, Graham, Jr,
SD. Does a staging pelvic lymphadenectomy make a significant difference in the
outcome of patients with prostatic adenocarcinoma. Southeastern Section AUA
Meeting, 1994.
22. Oladele A., Petros JA, Keane TK, Napalkov P., Dillehay D., Graham, Jr. S.D.
Intravesical Dextran for Chemoprevention of Transitional Cell Carcinoma of the
Bladder. American Association for Cancer Research, Inc., Abstract # 3570, March
26
T.KEANE REV 05/27/2010
1995.
23. Alawode Oladele, John A. Petros, Thomas E. Keane, Pavel Napalkov, Dirk Dillehay,
Sam D. Graham, Jr. Intravesical Dextran for Chemoprevention of Transitional Cell
Carcinoma of the Bladder. J. Urol. 153(4) 233A, Abstract 17, 1995.
24. Petros, J.A., Keane, T.K., Liotta, D., El-Galley, R., Graham, Jr., S.D. DNA Delivery
in Advanced Androgen Independent Prostate Cancer: Cellular and Nuclear
Targeting for Gene Therapy. American Association for Cancer Research, Inc.,
Abstract # 2511, March 1995.
25. John A. Petros, Thomas E. Keane, Dennis Liotta, Rizk El-Galley, Sam D. Graham,
Jr. DNA Delivery in Advanced Androgen Independent Prostate Cancer: Cellular
and Nuclear Targeting for Gene Therapy. J. Urol. 153(4) 307A, Abstract 313, 1995.
26. Murphy F. Townsend, Yi-Chong Wang, Christopher D. Hillyer, Aftaba A. Ansari,
Sam D. Graham, Jr., Dirk D. Dillehay, Marina Mosunjac, Periasamy Selvaraj, John
A. Petros, Thomas E. Keane, Kenneth W. Sell. Anti-CD28 mAb and IL-2 Provide
Costimulatory signals for Human T Cell Sensitization to Autologous Renal Cell
Carcinoma in Vitro. J. Urol. 153(4) 403A, Abstract 697, 1995.
27. Nikolas P. Symbas, John A. Petros, Thomas E. Keane, Sam D. Graham, Jr. The
Significance of Platelet Count on Survival of Patients with Renal Cell Carcinoma. J.
Urol. 153(4) 404A, Abstract 702, 1995.
28. Kevin P. Rozas, Gilbert J. Gonzalez, John A. Petros, Thomas E. Keane, Sam D.
Graham, Jr. Intraurethral Prostaglandin for the Treatment of Post-Prostatectomy
Impotence. J. Urol. 153(4) 473A, Abstract 977, 1995.
29. Keane, T.K., McGuire, W., Petros, J.A., Sun, C., Graham, Jr., S.D. CPT11/Cisplatin: An Effective Preclinical Combination in The Therapy of Advanced
Human Bladder Cancer (TCC). American Society of Clinical Oncology, Abstract #
1605, May, 1995.
30. El-Galley, R., Northway, R., Petros, JA, Sanders, H., Clarke, HS, Jr., Keane, TE,
Graham, SD, Jr. PSA Recurrence after Radical Prostatectomy. J. Urol. 155(5) 420A
Abstract #437, 1996.
31. Todd Hoekstra, Alan Futral, Tom Keane and Sam Graham, Jr. Radical Perineal
Prostatectomy Clinical Care Pathway. J. Urol. 155(5)-555A Abstract #977, 1996
32. D. Ead, A. Oladele, C. Sun, P. LaFontaine, H. Sanders, T. Keane, S. Graham, Jr., J.
Petros. Markers of Apoptotic cell death in the micrometastasis of patients with
prostate cancer. J. Urol 155(5) 625A Abstract #1255, 1996.
33. Merrill, Jr., E. Wang, E. Swchmelz, C. Sun, J. Petros, S. Graham, Jr., T. Keane.
Cytotoxicity of Fumonisin B1 for renal cell carcinoma and other tumor cell lines: a
new class of possible chemotherapeutic agents. J. Urol 155(5)653A Abstract #1367,
1996.
34. Thomas E. Keane, Rizk El-Galley, Carrie Sun, Lavette Pittman, Joan Karr, John A.
Petros, Sam D. Graham, Jr. Camptothecin Analogues in the Therapy of Advanced
Renal Cell Carcinoma. Results of In Vivo Studies Using a Model of Human Renal
Cell Carcinoma (RCC). J. Urol 157(4)276 Abstract #1073, 1997.
35. Rizk E.S. El-Galley, Thomas E. Keane, John A. Petros, William H. Sanders, Harry
S. Clarke, & Sam D. Graham, Jr. Evaluation of Staging Lymphadenectomy in
Prostate Cancer. Southeastern Section American Urological Association, April 1998.
36. Boris Velimirovich, Holt Sanders, James W. Keller, John Petros, Thomas E. Keane
& Sam D. Graham, Jr. Results of Post-Prostatectomy Radiotherapy. Southeastern
27
T.KEANE REV 05/27/2010
Section American Urological Association, April 1998.
28
T.KEANE REV 05/27/2010
37. Thomas E. Keane, Wayne B. Harris, Carrie Sun, Joan Karr, John A. Petros, Sam D.
Graham, Jr. Irenotecan (CPT-11) in Advanced Renal Cell Carcinoma: Results of
Multi Dose Study Defining the Minimal Effective Dose Using a Model of Advanced
Renal Cell Carcinoma (RCC). J. Urol 159(5)195 Abstract #751, 1998
38. Thomas E. Keane. Establishment of a New Renal Orthotopic and Metastatic
Human Tumor Model. American Urological Association, May 1999. Abstract #568,
p.148.
39. Thomas E. Keane. 9-Amino Camptothecin (9-AC): An Effective Therapy in an
Animal Model of Human Metastatic Renal Cell Carcinoma. American Urological
Association, May 2000. Abstract #475, p.109.
40. Thomas E. Keane. 9-Amino Camptothecin (9-AC): An Effective Therapy Against a
Pre-clinical in Vivo Model of Human Prostate Cancer. American Urological
Association, May 2000. Abstract #154, p.36.
41. Thomas E. Keane, Thomas Chun, S.D. Lim, J.N. Copeland, C. Cohen, Mahul B.
Amin. Prognostic Role of CD44 Cell Adhesion Molecule Protein Expression in
Primary and Metastatic Renal Cell Carcinoma (RCC): A Clinical Pathologic Study of
125 Cases. American Urological Association, May 2001. Abstract #506, p. 123.
42. Melinda M Lewis, Michael B Koch, Thomas E Keane, Robert Santoianni, Deborah
Carter, Cynthia Cohen. Evaluation Of Immunocyt™ vs. Conventional Cytology To
Detect Transitional Cell Neoplasia In Urine Specimens. US and Canadian Academy
of Pathology Meeting, Abstract #14:56A, March 2001.
43. Melinda M. Lewis, Kristin Fiebelkorn, Michael B. Koch, Cynthia Cohen, Harry S.
Clarke, Robert Santoianni, Deborah Carter, Thomas E. Keane. Evaluation Of
Immunocyt™ vs. Conventional Cytology To Detect Transitional Cell Neoplasia In
Urine Specimens. American Urological Association, June 2001.
44. SE Mendrinos, C Angeletti, T Keane, JA Petros, MB Amin. Identification of a Novel
Protein Profile of Urothelial Carcinoma (UCa) in Urine Using SELDI-TOF Mass
Spectrometry. Mod Pathol 15:174A, US and Canadian Academy of Pathology
Meeting, Chicago, IL, February 2002.
45. C Ritenour, T Lendvay, H Clarke, T Keane. The Role of Collaborative Radical
Surgery in Advanced Abdominal and Pelvic Malignancies. American Urological
Association, Abstract #2428May 2002.
46. T Keane, R El-Galey, S El-Doreeif. Radical Perineal Prostatectomy Outcome and
Morbidity. American Urological Association, Abstract #2479, May 2002.
47. PH Lin, TT Terramani, RL Bush, TE Keane, RG Moore, AB Lumsden. Concomitant
Intraoperative Renal Artery Embolization and Resection of Complex Renal
Carcinoma. Southern Vascular Society, Tuscon, AZ, January, 2003.
48. T. E. Keane, R. El-Galey, S. El-Doreeif, P.P. Daily. Radical Perineal Prostatectomy
A Minimally Invasive Option For Surgical Treatment of Prostate Cancer. Southeast
Section American Urological Association. March 2003.
49. J Laudido, DJ Wolff, S Minamiguchi, TE Keane, M Reeves, RS Hoda. FISHing for
Bladder Cancer Cells: Comparison of Voided Urine Cytology and Flourescence In
Situ Hybridization. United States and Canadian Academy of Pathology Annual
Meeting. September 2003.
50. T. Keane, D.J. Wolff, C. Felicissimo. Detection of Urothelial Carcinoma: Correlation
Between Cytology and Fluorescence in Situ Hybridization. American Society of
Human Genetics, November 8, 2003.
29
T.KEANE REV 05/27/2010
51. Fleshner N, Keane TE, Lawton CA, Payne H, Mulders PF, Taneja S. Adjuvant
Androgen Deprication Therapy offers a “Cure” in Patients with poor prognosis nonmetastatic prostate cancer. April 2005.
52. Reeves M, Edmunds D, Wolff D, Clarke H, Keane TE. Significance of Atypical Urine
Cytology. AUA March 2005.
53. Reeves M, Edmunds D, Wolff D, Clarke H, Keane TE. Comparison of Flourescent
In-Situ Hybridization (FiSH) and Cytology as a Screening Tool in New Patients.
Southeastern Section of AUA. March 2005.
54. M Reeves, H Edmunds, D Wolff, H Clarke, TE Keane. Analysis of False Positive
Flourescent In-Situ Hybridization (FiSH) Assays. Southeastern Section of AUA
March 2005.
55. M Reeves, O Moussa, D Wolff, H Clarke, D Watson, T Keane. Clinical Assessment
of Survivin as a Marker for Urothelial Carcinoma Patients.Southeast Section AUA.
March 2005.
56. M Wingo, M Eskridge, S Sudarshan, E Rovner, T Keane, R Rames. Salvaging the
Failed Staged Sacral Neuromodulator Implant: A Single Center Experience.
Southeast Section of AUA. March 2005.
57. W Brabham, M Reeves, M Pruitt, F Medio, TE Keane, H Clarke. Evaluation of the
Department of Urology Grand Rounds in Satisfying Accreditation Council for
Graduate Medical Education (ACGME) Core Clinical Competencies. Southeast
Section AUA. March 2005.
58. Wingo MS, Hamilton N, Eskridge M, Gordon L, Clarke H, Keane TE. Assisting
Salvage Treatment Selection in Biochemical Failure Following Radical
Prostatectomy: Prostatscint Scanning vs. Clinical Parameters. Southeast Section
AUA. March 2006.
59. Springer JR, Wingo MS, Keane TE. Trial of 45 Days of Antibiotic Therapy in
Patients with Asymptomatic Biopsy-Proven Prostatitis. Southeast Section AUA.
March 2006.
60. Springer JR, Wingo MS, Keane TE, Clarke HS. Trial of 45 Days of Antibiotic
Therapy in Patients with Asymptomatic Biopsy-Proven Prostatitis. AUA. May 2006.
61. A.E. Mahdy, X. Liu, J. Cheng, A.M El-Zawahry, L.S. Turner, A.F. Saad, S. Elojeimy,
Y.A. Hannun, T.E. Keane, M. Taha, H.M. Hammouda, J.S. Norris. Radiation
Therapy Upregulates Coxsackie-Adenovirus Receptor in Prostate Cancer Cells and
Sensitizes Prostate Cancer to Fas Ligand Gene Therapy. AUA. May 2007.
62. G.W. Bong, H.B. Hooper, R.O. Parker, N. Harty, T.E. Keane. Variability of
Pathologist Evaluating Surgical Margins May Impact Patient Care After Radical
Prostatectomy. AUA. May 2008.
63. G.W. Bong, H.S. Clarke, W. Hancock, T.E. Keane. Serum Testosterone Recovery
After Cessation of Long-Term Luteinizing Hormone-Releasing Hormone Agonist in
Patients with Prostate Cancer. Southeast Section AUA. March 2008.
64. Yoost T.R., Clarke H.S., Shaffer K. E., Keane T. E., Savage S. J.: Laparoscopic
Cryoablation of Renal masses: Which lesions fail? SESAUA. San Diego, CA March
2008.
65.El-Zawahry A.M., Eskridge M.R., Onicescu G., Garrett-Mayer E., Gordon L.L.,
Clarke H.S., Keane T.E. Selection of Patients for Salvage Cryosurgical Ablation of
the Prostate (CSAP) Utilizing Capromab Pendetide Scanning. In Preparation, 2009.
30
T.KEANE REV 05/27/2010
66.Ramsey SD, Zeliadt SB, Blough DK, Fedorenko CR, Moinpour CM, Hall IJ, Lee
SmithJ, Ekwueme DU, Fairweather ME, Thompson IM, Keane TE, Penson DF. A
comparison of physician and patient decision making for first versus second
opinions among men with local stage prostate cancer. International Society for
Pharmacoeconomics and Outcomes Research (ISPOR) 15th Annual International
Meeting. 2010 May 15-19; Atlanta, GA.
Local Publications:
1. T. E. Keane. Splenic Trauma: Is There a Choice of Therapy? St.Vincent's Hospital
Surgical Forum 1983-1984: 80-7.
2. T. E. Keane. Prostatic Carcinoma: An Overview. St.Vincent's Hospital Surgical
Forum 1985-86.
Editorial Comment:
1. Keane TE. Current Maintenance Regimens in the Therapy of Superficial
Transitional Cell Carcinoma of the Bladder. Oncology, Volume 15, Number 1, pp.
88-89. February 2001.
2. Keane TE. Organ Preservation in Muscle Invasive Bladder Cancer. Oncology 2004.
31
T.KEANE REV 05/27/2010